Back to search resultsSummaryRMgm-4886
|
||||||||
*RMgm-4886| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene mutation |
| Reference (PubMed-PMID number) | Not published (yet) |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | RMgm-4885 |
| Other information parent line | In this mutant the akarin gene has been deleted. This mutant does not contain a drug selectable marker (SM). The SM has been removed by negative selection |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Kehrer J, Frischknecht F |
| Name Group/Department | Center for Infectious Diseases, Integrative Parasitology |
| Name Institute | Heidelberg University Medical School |
| City | Heidelberg |
| Country | Germany |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-4886 |
| Principal name | akratinEYKY/AAAA |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not tested |
| Gametocyte/Gamete | Slightly reduced exflagellation |
| Fertilization and ookinete | Not different from wild type |
| Oocyst | Absence of oocyst formation |
| Sporozoite | Not tested |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation Phenotype The Akratin-EYKK/AAAA-GFP mutant showed similar staining patterns in asexual and sexual parasite stages compared with akratin-GFP. (see mutant RMgm-4888) However, in contrast to the mostly peripheral and vesicular localization of akratin-GFP in ookinetes the akratin-EYKK/AAAA GFP signal was diffusely localized within the cytoplasm Other mutants |
Mutated: Mutant parasite with a mutated gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1105300 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0505700 | ||||||||||||||||||||||||||
| Gene product | conserved Plasmodium membrane protein, unknown function | ||||||||||||||||||||||||||
| Gene product: Alternative name | akratin | ||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Short description of the mutation | C-terminal EYKK motif changed into four alanines and GFP tag | ||||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||||
| Short description of the conditional mutagenesis | Not available | ||||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||||
| Promoter of the selectable marker | unknown | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | The 5`UTR together with the entire ORF of PbANKA_1105300 was amplified from wt gDNA using primers JK66 and JK152 and inserted into the pL28 plasmid using KpnI and NdeI leading to the replacement of the selection marker. A TgDHFR selection cassette was amplified using primers JK153 and JK154 and inserted between the GFP and 3`UTR using NotI and EcorV resulting in plasmid 361 pL59. The 5`UTR together with the entire ORF was amplified from wt gDNA using primers JK66 and a reverse Primer introducing the mutations and inserted into the pL59 plasmid using KpnI and NdeI resulting in pL84. | ||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||